Clinical trials: Philadelphia-Positive ALL
Leukemia
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00003561
- Testing
- recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia.
- Trial name
- NCT00006052
- Testing
- imatinib mesylate
- Where
- United States
- Sponsor
- Novartis
Chronic Myeloid Leukemia
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
This study will assess the maximum tolerated dose of low dose interferon in conjunction with nilotinib in pretreated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia patients in chronic phase (CML-CP).
- Trial name
- NICOLI (NCT01220648)
- Testing
- Nilotinib, interferon-alfa
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Biological therapy may increase the number of immune cells found in bone marrow and may help a person's immune system recover from the side effects of the chemotherapy used in treating chronic myeloid leukemia.
- Trial name
- NCT00011934
- Testing
- recombinant interferon alfa, sargramostim, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
The objectives of Part 1 of the study were: To determine the rate of hematologic response (HR) lasting ≥4 weeks in participants with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the accelerated phase…
- Conditions
- Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00171249
- Testing
- STI571 400 mg, STI571 600 mg
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as 17-N-allylamino-17-demethoxygeldanamycin use different ways to stop…
- Trial name
- NCT00066326
- Testing
- imatinib mesylate, tanespimycin
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Chronic Myeloid Leukemia
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
The main purpose of this study was to evaluate the rate of deep molecular response (MR4.5) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase chronic myeloid leukemia (CML) using EUTOS…
- Trial name
- NILOdeepR (NCT02546674)
- Testing
- Nilotinib
- Where
- 70 sites in Germany
- Volunteers
- 171 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant…
- Trial name
- NCT01030718
- Testing
- dasatinib
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
This study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of Blinatumomab, in adult Ph+ ALL.
- Trial name
- NCT02744768
- Testing
- Dasatinib, Blinatumomab
- Where
- 34 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
The purpose of this study is to evaluate the efficacy, through molecular response and event-free survival, about the use of Imatinib in conjunction with chemotherapy after BFM "like" Induction in children with ALL Ph+.
- Trial name
- NCT01222013
- Testing
- Imatinib Mesylate
- Volunteers
- 20 people
- Sponsor
- Renato Melaragno
Ph+ ALL
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
This is an open-label, prospective clinical cohort study evaluating the efficacy and safety of reduced-intensity chemotherapy combined with targeted therapy and immunotherapy in adult patients with newly diagnosed Philadelphia…
- Trial name
- NCT07493161
- Testing
- Olverembatinib, Venetoclax, Blinatumomab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This study assesses the long-term safety and tolerability of dasatinib administered to patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia and experienced clinical benefit…
- Trial name
- START rollover (NCT00982488)
- Testing
- Dasatinib, Imatinib
- Where
- 72 sites in United States, Argentina and 22 more
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Mucositis
Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Mucositis, Oral Complications
- Trial name
- UKALL14 (NCT01085617)
- Testing
- palifermin, rituximab, cyclophosphamide
- Sponsor
- University College, London
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
This phase II trial studies how well the combination of decitabine, venetoclax, and ponatinib work for the treatment of Philadelphia chromosome-positive acute myeloid leukemia or myeloid blast phase or accelerated phase chronic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04188405
- Testing
- Decitabine, Ponatinib, Venetoclax
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Leukemia, Chronic
Registration of Children With CML and Treatment With Imatinib
Newly diagnosed pediatric patients (age < 19 years) with bcr-abl-positive CML will be treated with imatinib. Serial monitoring of treatment response is performed in one month intervals during the first three months of treatment…
- Trial name
- CML-paed II (NCT00445822)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Technische Universität Dresden
Philadelphia Positive Acute Lymphoblastic Leukemia, Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with…
- Trial name
- NCT00199186
- Testing
- imatinib, vincristine, cyclophosphamide
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Chronic Myeloid Leukemia
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
This is a Phase II, open-label, multi-center trial designed primarily to evaluate the rate of complete or major cytogenetic response of STI571 as demonstrated by a decrease in the percentage of Ph chromosome positive cells in the…
- Trial name
- NCT00511303
- Testing
- STI571
- Volunteers
- 200 people
- Sponsor
- University of Bologna
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
- Trial name
- NCT03519984
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
This project is a key clinical research project approved by the Clinical Research Center of the First Affiliated Hospital of Xi'an Jiaotong University.
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult
- Trial name
- NCT05026229
- Testing
- dasatinib plus consolidation chemotherapy with vincristine and prednisone, dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University